Citadel Advisors
CLRB icon

Citadel Advisors’s Cellectar Biosciences CLRB Stock Holding History

Citadel Advisors’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,526
Closed -$104K – 12802
2025
Q3 		$104K Buy
+18,526
New +$91.8K ﹤0.01% 11832
2025
Q2 		– Sell
-11,442
Closed -$108K – 12798
2025
Q1 		$108K Buy
+11,442
New +$104K ﹤0.01% 11348
2024
Q4 		– Sell
-10
Closed -$462 – 14605
2024
Q3 		$648 Sell
10
-1,664
-99% -$110K ﹤0.01% 13978
2024
Q2 		$126K Sell
1,674
-2,249
-57% -$216K ﹤0.01% 10593
2024
Q1 		$468K Buy
3,923
+1,623
+71% +$176K ﹤0.01% 8541
2023
Q4 		$191K Buy
+2,300
New +$171K ﹤0.01% 10025
2023
Q3 		– Sell
-1,026
Closed -$60K – 14362
2023
Q2 		$60K Buy
+1,026
New +$49.4K ﹤0.01% 11589
2023
Q1 		– Sell
-622
Closed -$31.9K – 14802
2022
Q4 		$31.9K Buy
+622
New +$37.3K ﹤0.01% 12662
2022
Q3 		– Sell
-230
Closed -$28K – 12716
2022
Q2 		$28K Buy
+230
New +$32.9K ﹤0.01% 12259
2022
Q1 		– Sell
-549
Closed -$109K – 13686
2021
Q4 		$109K Buy
+549
New +$132K ﹤0.01% 12625
2021
Q1 		– Sell
-114
Closed -$71K – 13208
2020
Q4 		$71K Buy
+114
New +$52.4K ﹤0.01% 10407
2020
Q2 		– Sell
-41
Closed -$15K – 9840
2020
Q1 		$15K Buy
+41
New +$27.4K ﹤0.01% 9357
2019
Q2 		– Sell
-59
Closed -$42K – 9226
2019
Q1 		$42K Buy
59
+10
+20% +$6.09K ﹤0.01% 8884
2018
Q4 		$23K Buy
+49
New +$34.9K ﹤0.01% 8692
2018
Q3 		– Sell
-19
Closed -$35K – 9248
2018
Q2 		$35K Buy
+19
New +$58.3K ﹤0.01% 8517
2018
Q1 		– Sell
-5
Closed -$19K – 8314
2017
Q4 		$19K Buy
+5
New +$22.3K ﹤0.01% 7836
2017
Q2 		– Sell
-6
Closed -$43K – 7543
2017
Q1 		$43K Buy
+6
New +$35.6K ﹤0.01% 7077

Other funds holding CLRB

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors's CLRB Position: Q4 2025 in Review

Citadel Advisors sold out of Cellectar Biosciences (CLRB) in Q4 2025, closing a stake of 18,526 shares — an estimated $104K sold.

Citadel Advisors first reported a position in CLRB in Q1 2017 and held it in 17 quarters. The position peaked at $468K in Q1 2024. 20 funds tracked by Wall St. Rank hold CLRB as of Q4 2025.

  • Citadel Advisors reported no remaining Cellectar Biosciences position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 18,526 Cellectar Biosciences shares in Q4 2025, an estimated $104K.
  • Citadel Advisors first reported a position in Cellectar Biosciences in Q1 2017 and held it in 17 quarters.
  • Citadel Advisors's Cellectar Biosciences position peaked at $468K in Q1 2024.
  • 20 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.